Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Primary Myelofibrosis 19Myeloproliferative Disorders 16Polycythemia Vera 10Leukemia 8Leukemia, Myeloid, Acute 7Breast Neoplasms 6Pancreatic Neoplasms 5Myelodysplastic Syndromes 5Hematologic Diseases 5Thrombocythemia, Essential 4Multiple Myeloma 4Bone Marrow Diseases 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Myelodysplastic-Myeloproliferative Diseases 3Leukemia, Myelomonocytic, Chronic 3Graft vs Host Disease 3Thrombocytosis 2Prostatic Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Bronchiolitis Obliterans Syndrome 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Preleukemia 1Precancerous Conditions 1Pathologic Complete Response 1

Interventions

mogamulizumab 3Cyclophosphamide 3Lenalidomide 2Alemtuzumab 2ruxolitinib 1peginterferon alfa-2b 1fludarabine phosphate 1fludarabine 1etoposide phosphate 1denileukin diftitox 1belinostat 1Zidovudine 1Vincristine 1Raltegravir Potassium 1Prednisone 1Oxaliplatin 1Introns 1Interleukin-15 1Gemcitabine 1Etoposide 1Doxorubicin 1Dexamethasone 1Daclizumab 1Cytarabine 1Cisplatin 1Calcium Dobesilate 1Bortezomib 1B3(Fv)-PE38KDEL recombinant immunotoxin 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia-Lymphoma, Adult T-Cell × ruxolitinib × Clear all
NCT01712659 2023-01-10

Ruxolitinib for Adult T-Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
19 enrolled 17 charts
LymphoidOther hematologic neoplasm

Leukemia, T-Cell, Leukemia-Lymphoma, Adult T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡